Critical review of ropinirole and Pramipexole - Putative dopamine D 3-receptor selective agonists - For the treatment of RLS

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 5, 2009, Pages 493-505

  Varga, L I ^a   Ako Agugua, N ^a   Colasante, J ^a   Hertweck, L ^a   Houser, T ^a   Smith, J ^a   Watty, A A ^a   Nagar, S ^a   Raffa, R B ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Pramipexole; Restless legs syndrome; Ropinirole

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; GABAPENTIN; HYPNOTIC SEDATIVE AGENT; IRON; LEVODOPA; NAFADOTRIDE; OPIATE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

AKATHISIA; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DIZZINESS; DOPAMINERGIC TRANSMISSION; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FOLIC ACID DEFICIENCY; GENETIC LINKAGE; GENETIC PREDISPOSITION; HALLUCINATION; HUMAN; IRON DEFICIENCY; LEG CRAMP; LIBIDO; LOW DRUG DOSE; NAUSEA; NONHUMAN; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; RESTLESS LEGS SYNDROME; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SEX DIFFERENCE; SEXUAL DESIRE; SIDE EFFECT; SOMNOLENCE; SWEATING; UNSPECIFIED SIDE EFFECT;

ANIMALS; BENZOTHIAZOLES; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; DOPAMINE; DOPAMINE AGONISTS; HUMANS; INDOLES; RECEPTORS, DOPAMINE D3; RESTLESS LEGS SYNDROME;

EID: 70049094184     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01025.x     Document Type: Review

References (94)

1. Kushida CA, Allen RP, Atkinson MJ (2004) Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Medicine, 5, 485 488.
2. Abetz L, Vallow S, Kirsch J, Allen R, Washburn T, Earley C (2005) Validation of the Restless Legs Syndrome Quality of Life Questionnaire. Value Health, 8, 157 167.
3. Abetz L, Arbuckle R, Allen RP et al. (2006) The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Medicine, 7, 340 349.
4. Winkelman JW (2006) Considering the causes of RLS. European Journal of Neurology, 13 (suppl. 3 8 14.
5. Allen RP (2007) Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. American Journal of Medicine, 120, S13 S21.
6. Trenkwalder C, Paulus W, Walters AS (2005) The restless legs syndrome. Lancet Neurology, 4, 465 475.
7. Trenkwalder C, Walters AS, Hening W (1996) Periodic limb movements and restless legs syndrome. Neurologic Clinics, 14, 629 650. (Pubitemid 26269996)
8. Kvernmo T, Härtter S, Bürger E (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clinical Therapeutics, 28, 1065 1078.
9. Allen RP, Earley CJ (2001) Restless legs syndrome: a review of clinical and pathophysiologic features. Journal of Clinical Neurophysiology, 18, 128 147.
10. Coccagna G, Vetrugno R, Lombardi C, Provini F (2004) Restless legs syndrome: an historical note. Sleep Medicine, 5, 279 283.
11. Willis T (1685) The London practice of physic. London : Bassett and Crooke.
12. Wittmaack T (1861) Pathologie and therapie der sensibilitä tneuronsen. Leipzig : William Wood.
13. Ekbom KA (1945) Restless legs: clinical study of hitherto overlooked disease in legs characterized by peculiar parethesia ('Anxietas tibiarum'), pain and weakness and occurring in two main forms, asthenia crurum paresthetica and asthenia crurum dolorosa; short review of paresthesias in general. Acta Medica Scandinavica, 158, 1 123.
14. Tuvo F (1949) Contibuto clinico alla conoscenza della syndrome cosiddetta 'irritable legs'. Minerva Medica, 40, 741 743.
15. Bonduelle M (1947) Syndrome des jambs sans repos. Paresthésie agitante nocturne des members inférieurs. Revue du Rhumatisme, 14, 188 189.
16. Bonduelle M (1952) Paresthésie agitante nocturne des members inférieurs et impatiences. Presse Medicale, 60, 62 64.
17. Bonduelle M, Jolivet B (1953) Les impatiences. Bull Med, 12, 316 318.
18. Bornstein B (1961) Restless legs. Psychiatria et Neurologia (Basel), 141, 165 201.
19. Menninger-Lerchenthal E (1962) Ruhelosigkeit der Beine (restless legs, tachyathetosis). Wiener Zeitschrift fur Nervenhkeilkunde und Deren Grenzgebiete, 19, 62 75.
20. Akpinar S (1987) Restless legs syndrome treatment with dopaminergic drugs. Clinical Neuropharmacology, 10, 69 79.
21. Tison F, Crochard A, Léger D, Bouée S, Lainey E, El Hasnaoui A (2005) Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology, 65, 239 246.
22. Thomas K, Watson CB (2008) Restless legs syndrome in women: a review. Journal of Women's Health, 17, 859 868.
23. Allen RP, Walters AS, Montplaisir J et al. (2005) Restless legs yndrome prevalence and impact: REST general population study. Archives of Internal Medicine, 165, 1286 1292.
24. Van De Vijver DA, Walley T, Petri H (2004) Epidemiology of restless legs syndrome as diagnosed in UK primary care. Sleep Medicine, 5, 435 440.
25. Picchietti MA, Picchietti DL (2008) Restless legs syndrome and periodic limb movement disorder in children and adolescents. Seminars in Pediatric Neurology, 15, 91 99.
26. Wolf DS, Singer HS (2008) Pediatric movement disorders: an update. Current Opinion in Neurology, 21, 491 496.
27. Gemignani F, Brindani F (2007) Restless legs syndrome associated with peripheral neuropathy [letter]. European Journal of Neurology, 14, e9 e10.
28. Allen RP, Earley CJ (2000) Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Medicine, 1, 11 19.
29. Allen AP, La Buda MC, Becker P, Earley CJ (2002) Family history study of the restless legs syndrome. Sleep Medicine, 3, S3 S7.
30. Stefansson H, Rye D, Hicks A et al. (2007) A genetic risk factor for periodic limb movements in sleep. New England Journal of Medicine, 357, 639 647.
31. Winkelmann J (2008) Genetics of restless legs syndrome. Current Neurology and Neuroscience Reports, 8, 211 216.
32. Pichler I, Hicks AA, Pramstaller PP (2008) Restless legs syndrome: an update on genetics and future perspectives. Clinical Genetics, 73, 297 305.
33. Ondo WG, Vuong KD, Wang Q (2000) Restless legs syndrome in monozygotic twins: clinical correlates. Neurology, 55, 1404 1406.
34. Winkelman JW (2007) Periodic limb movements in sleep - endophenotype for restless legs syndrome? New England Journal of Medicine, 357, 703 706.
35. Clemens S, Rye D, Hochman S (2006) Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology, 67, 125 130.
36. Winkelmann J, Schadrack J, Wetter TC, Zieglgänsberger W, Trenkwalder C (2001) Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Medicine, 2, 57 61.
37. Paulus W, Schomburg ED (2006) Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation? Sleep Medicine Reviews, 10, 185 196.
38. Wetter TC, Stiasny K, Winkelman J et al. (1999) A randomized, controlled study of pergolide in patients with restless legs syndrome. Neurology, 52, 944 950.
39. Garcia-Borreguero D, Odin P, Schwarz C (2004) Restless legs syndrome: an overview of the current understanding and management. Acta Neurologica Scandinavica, 109, 303 317.
40. Cervenka S, Pålhagen SE, Comley RA et al. (2006) Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain, 129, 2017 2028.
41. Kang S-G, Lee H-J, Jung SW et al. (2008) Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 31, 1078 1083.
42. Paulus W, Trenkwalder C (2006) Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurology, 5, 878 886. (Pubitemid 44715823)
43. Paulus W, Dowling P, Rijsman R, Stiasny-Kolster K, Trenkwalder C, de Weerd A (2007) Pathophysiological concepts of restless legs syndrome. Movement Disorders, 22, 1451 1456. (Pubitemid 47280631)
44. Zhao H, Zhu W, Pan T et al. (2007) Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. Journal of Neuroscience Research, 85, 1065 1076.
45. Noga BR, Pinzon A, Mesigil RP, Hentall ID (2004) Steady-state levels of monoamines in the rat lumbar spinal cord: spatial mapping and the effect of acute spinal cord injury. Journal of Neurophysiology, 92, 567 577.
46. Fleetwood-Walker SM, Hope PJ, Mitchell R (1988) Antinociceptive actions of descending dopaminergic tracts on cat and rat dorsal horn somatosensory neurones. Journal of Physiology, 399, 335 348.
47. Winkelman JW, Chertow GM, Lazarus JM (1996) Restless legs syndrome in end-stage renal deisease. American Journal of Kidney Disease, 28, 372 378.
48. O'Keefe ST, Gavin K, Lavan JN (1994) Iron status and restless legs syndrome in the elderly. Age and Ageing, 23, 200 203.
49. Rangarajan S, D'Souza GA (2007) Restless legs syndrome in Indian patients having iron deficiency anemia in a tertiary care hospital. Sleep Medicine, 8, 247 251.
50. Lee KA, Zaffke ME, Baratte-Beebe K (2001) Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron. Journal of Women's Health & Gender-Based Medicine, 10, 335 341.
51. Earley CJ, Ponnuru P, Wang X et al. (2008) Altered iron metabolism in lymphocytes from subjects with restless legs syndrome. Sleep, 31, 847 852.
52. Silber MH, Richardson JW (2003) Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. Mayo Clinic Proceedings, 78, 52 54.
53. Early CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP (2000) Abnormalities in CSF concentration of ferritin and transferring in restless legs syndrome. Neurology, 54, 1698 1700.
54. Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP (2008) A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine, in press.
55. Wiesinger JA, Buwen JP, Cifelli CJ, Unger EL, Jones BC, Beard JL (2007) Down-regulation of dopamine transporter by iron chelation in vitro is mediated by altered trafficking, not synthesis. Journal of Neurochemistry, 100, 167 179.
56. Ondo WG, Zhao HR, Le WD (2007) Animal models of restless legs syndrome. Sleep Medicine, 8, 344 348.
57. Hening WA (2007) Current guidelines and standards of practice for restless legs syndrome. American Journal of Medicine, 120 (Suppl. 1 S22 S27.
58. Earley CJ (2003) Clinical practice. Restless legs syndrome. New England Journal of Medicine, 348, 2103 2109.
59. Silber MH (2004) An algorithm for the management of restless legs syndrome. Mayo Clinic Proceedings, 79, 916 922. [erratum appears in Mayo Clinic Proceedings, 79, 1341].
60. Allen R (2004) Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Medicine, 5, 385 391.
61. Garcia-Borreguero D, Larrosa O, Granizo JJ, de la Llave Y, Hening WA (2004) b) Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome. Sleep, 27, 669 693.
62. Lesage S, Hening WA (2004) The restless legs syndrome and periodic limb movement disorder: a review of management. Seminars in Neurology, 24, 249 259.
63. Happe S, Trenkwalder C (2004) Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs, 18, 27 36. (Pubitemid 38197757)
64. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacological Reviews, 49, 231 252.
65. 3 receptor. Molecular Endocrinology, 21, 2242 2254.
66. 3 receptor coexistence. Brain Research Reviews, 26, 236 242.
67. 3 receptor antagonist, activates locomotion in rodents. Journal of Pharmacology and Experimental Therapeutics, 275, 1239 1246.
68. 3 dopamine receptor gene is associated with hyperactivity in mice. Proceedings of the National Academy of Sciences (USA), 93, 1945 1949.
69. Jost WH, Angersbach D (2005) Ropinirole, a non-ergoline dopamine agonist. CNS Drug Reviews, 11, 253 272.
70. Dobson AM, Cuellar N (2006) Use of ropinirole in RLS. Nurse Practitioner, 31, 46 48.
71. Ravikumar K, Sridhar B (2006) Ropinirole hydrochloride, a dopamine agonist. Acta Crystallographica C, 62, o265 o267.
72. ® Prescribing Information via http://www.requip.com (last accessed February 9, 2009).
73. Eden RJ, Costall B, Domeney AM et al. (1991) preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacology, Biochemistry and Behavior, 38, 147 154.
74. 3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. Pharmacology and Therapeutics, 112, 281 333.
75. Fears RB (1993) Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease. Patent WO9323035 (http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9323035&F=0).
76. Perachon S, Betancur C, Pilon C, Rostene W, Schwartz J-C, Sokoloff P (2000) Role of dopamine D3 receptors in thermoregulation: a reappraisal. NeuroReport, 11, 221 225.
77. Trenkwalder C, Garcia-Borreguero D, Montagna P et al. (2004) Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomized, placebo controlled study in 10 European countries. Journal of Neurology and Neurosurgical Psychiatry, 75, 92 97.
78. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K (2004) Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Movement Disorders, 19, 1414 1423.
79. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY (2006) Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clinic Proceedings, 81, 17 27.
80. Allen R, Becker PM, Bogan R et al. (2004) Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep, 27, 907 914.
81. Montplaisir J, Karrasch J, Haan J, Volc D (2006) Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Movement Disorders, 10, 1627 1635.
82. Driver-Dunckley ED, Noble BN, Hentz JG et al. (2007) Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clinical Neuropharmacology, 30, 249 255.
83. ® Prescribing Information via http://www.mirapex. com (last accessed September 28, 2008).
84. 4 receptors. European Journal of Pharmacology, 290, 29 36.
85. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B (1999) Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology, 52, 938 943.
86. Trenkwalder C, Benes H, Grote L et al. (2007) Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Movement Disorders, 22, 696 703.
87. Baker WL, White CM, Coleman CI (2008) Effect of nonergot dopamine agonists on symptoms of restless legs syndrome. Annals of Family Medicine, 6, 253 262.
88. Clavadetscher SC, Gugger M, Bassetti CL (2004) Restless legs syndrome: clinical experience with long-term treatment. Sleep Medicine, 5, 495 500.
89. Merlino G, Serafini A, Robiony F, Valente M, Gigli GL (2008) Clinical experience with pramipexole in the treatment of restless legs syndrome. Expert Opinion On Drug Metabolism and Toxicology, 4, 225 235.
90. Hyman N (2008) Restless legs syndrome: symptoms, management and new developments. British Journal of Hospital Medicine, 69, 147 150.
91. Ball E, Caivano CK (2008) Internal medicine: guidance to the diagnosis and management of restless legs syndrome. Southern Medical Journal, 101, 631 634.
92. Restless legs syndrome fact sheet at http://www.ninds.nih.gov/disorders/ restless-legs/detail-restless-legs.htm?css=print (last accessed September 28, 2008).
93. Schormair B, Kemlink D, Roeske D et al. (2008) PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nature Genetics, 40, 946 948.
94. Winkelmann J, Lichtner P, Schormair B et al. (2008) Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome. Movement Disorders, 23, 350 358.